1. Scrip
  2. >>Business

AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials

 
• By Joseph Haas

Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.

Business growth
AbbVie's investors want to see if Q2 optimism about Botox proved true

AbbVie Inc. reported that Botox aesthetic and therapeutic sales in the second quarter were diminished by the novel coronavirus pandemic but indicated that the product’s revenue trends already were showing strong signs of recovery. As the company reports its third quarter numbers on 30 October, investors will be looking to see that Botox – a key driver of AbbVie’s $63bn buyout of Allergan plc – is returning to growth as projected.

Botox (onabotulinumtoxinA) therapeutic business posted $427m in sales during the second quarter, down 23% year-over-year and 13% sequentially, while the product’s aesthetic revenue of $240m declined 44% year-over-year and 27% sequentially. (Also see "AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials" - Scrip, 31 July, 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.